Expression of transcription nuclear factor NFκB in laryngeal carcinoma tumor cells - Correlation with IL-10 expression by blood mononuclear cells and clinicomorphological features;Ekspresja transkrypcyjnego czynnika jądrowego NFκB w komórkach raka krtani - korelacja z ekspresją IL-10 oraz cechami kliniczno-morfologicznymi guza

Otolaryngologia Polska

Volumn 63, Issue 7, 2009, Pages 28-34

  Starska, Katarzyna ^a,e   Stasikowska, Olga ^b   Lewy Trenda, Iwona ^c   Głowacka, Ewa ^d   Łukomski, Marek ^a  

^a Klinika Laryngologii Onkologicznej   (Poland)

^b Zaklad Nefropatologii   (Poland)

^c Katedra Patomorfologii Klinicznej   (Poland)

^d Zaklad Immunologii Klinicznej   (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

IL 10; Laryngeal carcinoma; Transcription nuclear factor NF B

Indexed keywords

INTERLEUKIN 10; TRANSCRIPTION FACTOR RELA; TUMOR MARKER;

AGED; ARTICLE; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; LARYNX TUMOR; MALE; METABOLISM; MIDDLE AGED; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-10; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; TRANSCRIPTION FACTOR RELA; TUMOR MARKERS, BIOLOGICAL;

EID: 77954930881     PISSN: 00306657     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0030-6657(09)70185-4     Document Type: Article

References (45)

1. Jiang H, Yang BB. p53, epidermal growth factor receptor and proliferating cell nuclear antigen in laryngeal squamous cell carcinoma are not predictive markers for the effect of adjuvant radiotherapy. Acta Otolaryngol. 2009;129(1):101-107.
2. Lukomski M, Lewy-Trenda I, Stasikowska O, Durko M, Starska K. Morphological tumor front grading and matrix metalloproteinases type I expression as a prognostic parameter of the presence of lymph node micrometastases in laryngeal carcinoma. Otolaryngol Pol. 2007; 61(5): 805-810.
3. Micozkadioglu D, Unal M, Pata YS, Bastürk M, Cinel L. Prognostic value of expression of p53, proliferating cell nuclear antigen, and c-erbB-2 in laryngeal carcinoma. Med Sci Monit. 2008; 14(6): CR299-304.
4. Kumar B, Cordell KG, D'Silva N, Prince ME, Adams ME, Fisher SG i wsp. Expression of p53 and Bcl-xL as predictive markers for larynx preservation in advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg. 2008; 134(4): 363-369.
5. Marioni G, Giacomelli L, D'Alessandro E, Staffieri C, Guzzardo V, Staffieri A i wsp. Laryngeal carcinoma recurrence rate and disease-free interval are related to CD105 expression but not to vascular endothelial growth factor 2 (Flk-1/Kdr) expression. Anticancer Res. 2008; 28(1B): 551-557.
6. Yoshimura A, Nishinakamura H, Matsumura Y, Hanada T. Negative regulation of cytokine signaling and immune responses by SOCS proteins. Arthritis Res Ther. 2005; 7(3): 100-110.
7. Lam LT, Wright G, Davis RE, Lenz G, Farinha P, Dang L, Chan JW, Rosenwald A, Gascoyne RD, Staudt LM.Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa} B pathways in subtypes of diffuse large B-cell lymphoma. Blood. 2008; 111(7): 3701-3713.
8. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol. 2007; 22(12): 1387-1398.
9. Lee CH, Jeon YT, Kim SH, Song YS. NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 2007; 29(1): 19-35.
10. Kim HJ, Hawke N, Baldwin AS. NF-kappaB and IKK as therapeutic targets in cancer. Cell Death Differ. 2006 May; 13(5): 738-747.
11. Celec P. Nuclear factor kappa B - molecular biomedicine: the next generation. Biomed Pharmacother. 2004; 58(6-7): 365-371.
12. Adli M, Baldwin AS. IKK-i/IKKepsilon controls constitutive, cancer cell-associated NF-kappaB activity via regulation of Ser-536 p65/RelA phosphorylation. J Biol Chem. 2006; 281(37): 26976-26984.
13. Bass res DS, Baldwin AS. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene. 2006; 25(51): 6817-6830.
14. Anest V, Cogswell PC, Baldwin AS Jr. I kappa B kinase alpha and p65/RelA contribute to optimal epidermal growth factor-induced c-fos gene expression independent of I kappa Balpha degradation. J Biol Chem. 2004; 279(30): 31183-31189.
15. Crisostomo PR, Wang Y, Markel TA, Wang M, Lahm T, Meldrum DR. Human mesenchymal stem cells stimulated by TNF-alpha, LPS, or hypoxia produce growth factors by an NF kappa B-but not JNK-dependent mechanism. Am J Physiol Cell Physiol. 2008; 294(3): C675-682.
16. Paik J, Lee JY, Hwang D. Signaling pathways for TNFainduced COX-2 expression: mediation through MAP kinases and NFkB, and inhibition by certain nonsteroidal anti-inflammatory drugs. Adv Exp Med Biol. 2002; 507: 503-508.
17. Thoms HC, Dunlop MG, Stark LA. CDK4 inhibitors and apoptosis: a novel mechanism requiring nucleolar targeting of RelA. Cell Cycle. 2007 Jun 1; 6(11): 1293-1297.
18. Thoms HC, Dunlop MG, Stark LA. p38-mediated inactivation of cyclin D1/cyclin-dependent kinase 4 stimulates nucleolar translocation of RelA and apoptosis in colorectal cancer cells. Cancer Res. 2007; 67(4): 1660-1669.
19. Stark LA, Dunlop MG. Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis. Mol Cell Biol. 2005; 25(14): 5985-6004.
20. Starska K, łukomski M. Regulacja cyklu komórkowego, procesu apoptozy, wydzielania cytokin i cza{ogonek}steczek adhezyjnych w limfocytach T i innych komórkach krwi obwodowej oraz komórkach nowotworowych w mechanizmie aktywacji Toll-like receptors (TLRs) i rodziny cza{ogonek}steczek transkrypcyjnego czynnika ja{ogonek}drowego NF-B. Poste{ogonek}py Biologii Komórki 2006; 33(4): 621-634.
21. Murray PJ. STAT3-mediated anti-inflammatory signalling. Biochem Soc Trans. 2006; 34(6): 1028-1031.
22. Lang R, Rutschman RL, Greaves DR, Murray PJ. Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL-10 under control of the human CD68 promoter. J Immunol. 2002; 168(7): 3402-3411.
23. Rubtsov YP, Rasmussen JP, Chi EY, Fontenot J, Castelli L, Ye X, Treuting P, Siewe L, Roers A, Henderson WR Jr, Muller W, Rudensky AY. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008; 28(4): 546-558.
24. Williams LM, Ricchetti G, Sarma U, Smallie T, Foxwell BM. Interleukin-10 suppression of myeloid cell activation-a continuing puzzle. Immunology. 2004; 113(3): 281-292.
25. Murray PJ. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr Opin Pharmacol. 2006; 6(4): 379-386.
26. Starska K. Rola rodziny cza{ogonek}steczek transkrypcyjnego czynnika ja{ogonek}drowego NF-kB w regulacji cyklu komórkowego i zjawiska apoptozy w przebiegu onkogenezy i progresji nowotworu. Otorynolaryngologia 2006; 5(2): 51-56.
27. John Wiley & Sons. TNM Classification of Malignant Tumours. 6th edition Hoboken, New Jersey; 2002.
28. Starska K, Kulig A, łukomski M. Anneroth, Batsakis and Luna's modified classification as prognostic factor in patients with laryngeal carcinoma. Otolaryngol Pol. 2003; 57(2): 229-235.
29. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004; 25(6): 280-288.
30. Mémet S. NF-kappaB functions in the nervous system: from development to disease. Biochem Pharmacol. 2006; 72(9): 1180-1195.
31. Gilmore TD. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene. 2006; 25(51): 6680-6684.
32. Hoffmann A, Natoli G, Ghosh G. Transcriptional regulation via the NF-kappaB signaling module. Oncogene. 2006; 25(51): 6706-6716.
33. Perkins ND, Gilmore TD. Good cop, bad cop: the different faces of NF-kappaB. Cell Death Differ. 2006; 13(5): 759-772.
34. Basak S, Kim H, Kearns JD, Tergaonkar V, O'Dea E, Werner SL, Benedict CA, Ware CF, Ghosh G, Verma IM, Hoffmann A. A fourth I kappa B protein within the NF-kappaB signaling module. Cell. 2007; 128(2): 369-381.
35. Escárcega RO, Fuentes-Alexandro S, García-Carrasco M, Gatica A, Zamora A. The transcription factor nuclear factor-kappa B and cancer. Clin Oncol (R Coll Radiol). 2007; 19(2): 154-61.
36. Sethi G, Sung B, Aggarwal BB. Nuclear factor-kappaB activation: from bench to bedside. Exp Biol Med (Maywood) 2008; 233(1): 21-31.
37. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 2007; 22(12): 1387-1398.
38. Lerebours F, Vacher S, Andrieu C, Espie M, Marty M, Lidereau R, Bieche I. NF-kappa B genes have a major role in inflammatory breast cancer. BMC Cancer 2008; 8: 41.
39. Wu W, Pan C, Yu H, Gong H, Wang Y. Heparanase expression in gallbladder carcinoma and its correlation to prognosis. J Gastroenterol Hepatol. 2008; 23(3): 491-497.
40. Xiao XB, Mai HQ, Cao SM, Zhang Y, Sun R, Hong MH. Gene expression profile of immune cells from patients with nasopharyngeal carcinoma of stage T3-4N0. Ai Zheng 2005; 24(2): 135-140.
41. Korkolopoulou P, Levidou G, Saetta AA, El-Habr E, Eftichiadis C, Demenagas P, Thymara I, Xiromeritis K, Boviatsis E, Thomas-Tsagli E, Panayotidis I, Patsouris E. Expression of nuclear factor-kappaB in human astrocytomas: relation to pI kappa Ba, vascular endothelial growth factor, Cox-2, microvascular characteristics, and survival. Hum Pathol 2008; 39(8): 1143-1152.
42. Meir T, Dror R, Yu X, Qian J, Simon I, Pe'er J, Chowers I. Molecular characteristics of liver metastases from uveal melanoma. Invest Ophthalmol Vis Sci 2007; 48(11): 4890-4896.
43. Jin X, Wang Z, Qiu L, Zhang D, Guo Z, Gao Z, Deng C, Wang F, Wang S, Guo C. Potential biomarkers involving IKK/RelA signal in early stage non-small cell lung cancer. Cancer Sci 2008; 99(3): 582-589.
44. Williams L, Bradley L, Smith A, Foxwell B. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J Immunol 2004; 172(1): 567-576.
45. Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J Leukoc Biol 2004; 76(2): 314-321.